89bio announces inducement grants under nasdaq listing rule 5635(c)(4)

San francisco, dec. 19, 2024 (globe newswire) -- 89bio, inc. (the “company” or “89bio”) (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the compensation committee of the company's board of directors approved the grant of non-qualified stock options to purchase an aggregate of 48,000 shares of the company's common stock to one new employee (the “inducement grant”) on december 13, 2024 (the “grant date”). the inducement grant has been granted pursuant to the company's 2023 inducement plan (the “plan”). the inducement grant was granted as an inducement material to the individual entering into employment with 89bio in accordance with nasdaq listing rule 5635(c)(4).
ETNB Ratings Summary
ETNB Quant Ranking